Ghaziabad Online

Brain Metastases Pipeline & Clinical Trials Report | 50+ Companies & 50+ Drugs

 Breaking News
  • No posts were found

Brain Metastases Pipeline & Clinical Trials Report | 50+ Companies & 50+ Drugs

January 12
20:46 2023
Brain Metastases Pipeline & Clinical Trials Report | 50+ Companies & 50+ Drugs

DelveInsight’s, “Brain Metastases Pipeline Insight, 2023,” report provides comprehensive insights about 50+ Brain Metastases companies and 50+ pipeline drugs in the Brain Metastases pipeline landscape. It covers the Brain Metastases pipeline drug profiles, including Brain Metastases clinical trials and nonclinical stage products. Brain Metastases pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Brain Metastases Pipeline Insight Report

 

  • DelveInsight’s Brain Metastases pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for brain metastases treatment.

 

  • The leading Brain Metastases Companies HUYA Bioscience, Kazia Therapeutics, BioMimetix, EpicentRx, Inc., Angiochem, Medolution Ltd., Betta Pharmaceuticals Co., Ltd., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, 2-BBB Medicines, DEKK-TEC, Inc., Nascent Biotech, Quadriga Biosciences, Inc., Jubilant Therapeutics, Denali Therapeutics Inc, NUVATION BIO, Novocure GmbH, Affinia Therapeutics, Specialised Therapeutics, Precirix, Ashvattha Therapeutics, Cereius, Allarity Therapeutics, TYK Medicine, Surgimab, ORIC Pharmaceuticals, SonALAsense, Nerviano Medical Sciences, Lin Bioscience, Inc., Zai Lab, Lantern Pharma, ABM Therapeutics, Carthera, and others.

 

  • Promising Brain Metastases Pipeline Therapies include HBI-8000, Paxalisib, BMX-001, RRx-001, ANG1005, JBI 2174, SCR 6852, Keynatinib, ATV HER2, Icotinib, Pembrolizumab, Pritumumab, Nivolumab, Palbociclib, DM-CHOC-PEN, MW151, Elacestrant, Atezolizumab, Trastuzumab Deruxtecan, AMG 510, 2B3-101, CER-101, 2X-111, Encorafenib, TY-9591, SGM-101, Binimetinib, ORIC-114, SONALA-001, NVL-520, Entrectinib, HKI-272, LBS-002, D6-B483, LP-184, and others.

 

  • The Brain Metastases Companies and academics are working to assess challenges and seek opportunities that could influence Brain Metastases R&D. The therapies under development are focused on novel approaches to treat/improve Brain Metastases.

 

Explore more about the latest breakthroughs of the Brain Metastases Treatment Landscape @ Brain Metastases Pipeline Outlook

 

Brain Metastases Overview

Brain metastases are the most common intracranial tumor in adults and may affect up to 200,000 patients per year. The three most common primary malignancies that metastasize to the brain are lung, breast, and melanoma. Additional cancers with brain metastases include renal cell, colorectal cancer, and gynecologic cancers. Signs and symptoms caused by brain metastases can vary based on the location, size and rate of growth of the metastatic tumors. About one third of patients with another type of cancer will develop one or more metastatic brain tumors. The risk for metastatic brain tumors begins to increase after age 45 and is highest in those over 65. Signs and symptoms of brain metastases include: Headache, sometimes with vomiting or nausea, mental changes, such as increasing memory problems, Seizures, and Weakness or numbness on one side of the body. Brain metastasis diagnosis is suspected through thorough physical examination and history. Brain metastasis can be diagnosed utilizing the following tests: Computed Axial Tomography, Magnetic Resonance Imaging and others. Treatment varies with the size and type of the tumor, the primary site of the malignancy, its extent both locally and in the rest of the body (staging), the general health of the individual and presence of other significant medical problems.

 

Recent Developmental Activities in the Brain Metastases Treatment Landscape

  • In October 2022, Nuvalent, Inc. announced the presentation of new preclinical data for , a NVL-330 novel, brain-penetrant HER2-selective tyrosine kinase inhibitor targeting HER2 exon 20 insertion mutations (HER2ex20). Preclinical data demonstrated that NVL-330 potently inhibited HER2ex20 in cell-based assays and was highly selective for HER2ex20 over the structurally related wild-type EGFR. In addition, the demonstrated preclinical brain penetrance and intracranial activity of NVL-330 suggest the potential for treating or preventing brain metastases.
  • In October 2022, Enliven Therapeutics, Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Enliven’s pipeline of precision oncology product candidates. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance, and disease escape through brain metastases. Enliven believes that if ELVN-002 inhibits HER2 and key mutations of HER2 while sparing wild-type EGFR and avoiding EGFR-related toxicities., it will be able to achieve an improved therapeutic index compared to current approved and investigational TKIs as well as provide a meaningful therapeutic option to patients with brain metastases, a key mechanism of resistance to current therapies in patients with NSCLC and other HER2 driven diseases.
  • In August 2022, Jubilant Therapeutics Inc. announced the US Food and Drug Administration clearance of the Investigational New Drug application (IND) for JBI-778, an oral, brain penetrant and selective protein arginine methyl transferase 5 (PRMT5) inhibitor, for the treatment of solid tumors with brain metastases and primary brain tumors including high-grade glioma.
  • In August 2022, Kazia Therapeutics announced the presentation of promising new data from an ongoing Phase I clinical trial of paxalisib in combination with radiotherapy for the treatment of brain metastases, sponsored by Memorial Sloan Kettering Cancer Center in New York, NY. Interim data from the first stage of the study reports that all 9 evaluable patients experienced complete or partial response, representing an overall response rate (ORR) of 100%. The safety profile of paxalisib in combination was broadly consistent with monotherapy experience in other clinical trials, and a maximum tolerated dose (MTD) of 45mg daily in combination with radiotherapy was confirmed.
  • 2X-111 (Glutathione-enhanced, PEGylated Liposomal Doxorubicin), novel drug candidate being developed by Allarity Therapeutics, is designed for the liposomal delivery of the anti-cancer drug doxorubicin directly to a tumor, with a glutathione coating added to exploit active endogenous transporters, allowing the drug to cross the blood-brain barrier. Allarity has out-licensed 2X-111 to Smerud Research International AS to progress late-stage clinical development for the potential treatment of glioblastoma multiform (GBM) (primary brain cancer) and potentially brain metastases of breast cancer (mBC).

 

Discover more about the Brain Metastases Emerging Therapies and Companies report @ Brain Metastases Treatment Landscape

 

Brain Metastases Emerging Drugs Profile

 

HBI-8000: HUYA Bioscience International

HBI-8000 is a Class I selective oral HDACi with immunomodulatory effects including enhanced cell-mediated toxicity, enhanced tumor infiltration by cytotoxic T-cells and reduced tumor infiltration by T-regulatory cells. Phase III clinical trials are being evaluated  for the treatment of patients with progressive brain metastasis. 

 

ANG1005: Angiochem

ANG1005 is a novel targeted taxane derivative that is the first oncology product to leverage Angiochem’s technology platform to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 is an Angiopep-2 paclitaxel conjugate that gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain. Currently, the drug is being evaluated in Phase III stage of Clinical trial evaluation for the treatment of Brain metastases.

 

AZD3759: Alpha BioPharma

Alpha Bio is conducting multi-center Phase II/III clinical study of AZD3759, a TKI for EGFR mutation-positive cases of non-small cell lung cancer with CNS metastasis particularly brain metastasis. 

 

Brain Metastases Therapeutics Assessment

There are approx. 50+ key Brain Metastases companies which are developing the therapies for Brain metastases. The companies which have their Brain metastases drug candidates in the most advanced stage, i.e. phase III include, Betta Pharmaceuticals.

 

Learn more about the Brain Metastases Emerging Therapies @ Brain Metastases Ongoing Clinical Trials Analysis

 

Scope of the Brain Metastases Pipeline Report

  • Coverage- Global
  • Brain Metastases Companies- HUYA Bioscience, Kazia Therapeutics, BioMimetix, EpicentRx, Inc., Angiochem, Medolution Ltd., Betta Pharmaceuticals Co., Ltd., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, 2-BBB Medicines, DEKK-TEC, Inc., Nascent Biotech, Quadriga Biosciences, Inc., Jubilant Therapeutics, Denali Therapeutics Inc, NUVATION BIO, Novocure GmbH, Affinia Therapeutics, Specialised Therapeutics, Precirix, Ashvattha Therapeutics, Cereius, Allarity Therapeutics, TYK Medicine, Surgimab, ORIC Pharmaceuticals, SonALAsense, Nerviano Medical Sciences, Lin Bioscience, Inc., Zai Lab, Lantern Pharma, ABM Therapeutics, Carthera, and others.
  • Brain Metastases Pipeline Therapies- HBI-8000, Paxalisib, BMX-001, RRx-001, ANG1005, JBI 2174, SCR 6852, Keynatinib, ATV HER2, Icotinib, Pembrolizumab, Pritumumab, Nivolumab, Palbociclib, DM-CHOC-PEN, MW151, Elacestrant, Atezolizumab, Trastuzumab Deruxtecan, AMG 510, 2B3-101, CER-101, 2X-111, Encorafenib, TY-9591, SGM-101, Binimetinib, ORIC-114, SONALA-001, NVL-520, Entrectinib, HKI-272, LBS-002, D6-B483, LP-184, and others.
  • Brain Metastases Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type, Molecule Type

 

Table of Content

  1. Introduction
  2. Brain Metastases Executive Summary
  3. Brain Metastases: Overview
  4. Brain Metastases Pipeline Therapeutics
  5. Brain Metastases Therapeutic Assessment
  6. Brain Metastases – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Brain Metastases Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Icotinib: Betta Pharmaceuticals
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II/III)
  13. AZD3759: Alpha BioPharma
  14. Drug profiles in the detailed report…..
  15. Early stage products (Phase I/II)
  16. BMX-001: BioMimetix
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Brain Metastases Key Companies
  20. Brain Metastases Key Products
  21. Brain Metastases- Unmet Needs
  22. Brain Metastases- Market Drivers and Barriers
  23. Brain Metastases- Future Perspectives and Conclusion
  24. Brain Metastases Analyst Views
  25. Brain Metastases Key Companies
  26. Appendix

 

For further information on the Brain Metastases Pipeline Therapeutics, reach out @ Brain Metastases Market Drivers and Barriers

 

 About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/